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Abstract 
Autonomous cell growth may result from interactions of cellular growth factors with their receptors leading to the establishment of 
external or internal autocrine loops which can induce tumor formation. Tumor progression above a small volume also requires an increase 
in blood supply. This is achieved by the release from the tumor of angiogenic growth factors which diffuse toward preexisting capillaries. 
The search for compounds interfering with growth factors and their receptors represents a field of investigation of increasing importance. 
In this report we show that almitrine interferes with the binding of basic fibroblast growth factor and vasculotropin/vascular endothelial 
growth factor to their receptors present on vascular endothelial cells, smooth muscle cells or retinal pigment epithelium. This molecule 
inhibits reversibly serum and basic growth factors stimulated cell growth and motility without affecting epidermal growth factor-stimu- 
lated proliferation. 
1. Introduction 
Autonomous cell growth may result from interactions of 
cellular growth factors with their receptors. Whether this is 
due to overexpression of the growth factors or their recep- 
tors, the enhancement of mitogenic signals induced by 
such interactions might occur through external or internal 
autocrine loops [l]. Tumor progression above a small 
volume also requires an increase in blood supply. This is 
achieved by the release from the tumor of angiogenic 
growth factors which diffuse toward preexisting capillaries 
[2], interact with their endothelial cell receptors and there- 
fore trigger along this gradient of concentration the migra- 
tion, proliferation and differentiation of endothelial cells. 
Several growth factors have been purified during the past 
decade; their genes have been cloned and sequenced and 
their biological activities at least partially deciphered [3]. 
Amongst them, the acidic and basic Fibroblast Growth 
Factors - aFGF, bFGF - have been shown to stimulate a 
wide variety of normal and tumoral cells [4,5]. On the 
other hand vasculotropin (VAS) also known as vascular 
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endothelial growth factor (VEGF) or vascular permeability 
factor (VPF), is a mitogen whose mitogenic activity seems 
to be restricted to vascular endothelial cells [6-91. Its 
selective inhibition by neutralizing antibodies [ 101 or trans- 
fection with a negative dominant receptor [ll] leads to 
tumor inhibition. Extensive efforts have been devoted to 
the search for molecules preventing the interactions of 
growth factors with their receptors. Although some com- 
pounds such as protamine [12], suramin [13] fumagillin 
[14] or minocycline [15] fulfil these requirements, their 
toxicity might impair their clinical usefulness. In the search 
for anti-VAS/VEGF molecules we found that almitrine 
inhibited the proliferation and the migration of cells ex- 
posed to bFGF or VAS/VEGF and not to epidermal 
growth factor (EGF). These reversible effects were medi- 
ated by a direct interaction with the growth factors and 
their receptors. 
2. Materials and methods 
2.1. Cell culture and growth factor purification 
Bovine fetal aortic endothelial (FBAE) and smooth 
muscle (VSM) cells were cultured in DMEM supple- 
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mented with 50 pg/ml gentamycin, 100 U/ml penicillin, 
100 pg/ml streptomycin and 10% calf serum in a 10% 
CO, atmosphere, as described [16]. Bovine brain 
capillary-derived endothelial cells (BBC) were cultured as 
in Ref. [17]. Stock cultures received 1 ng/ml of bFGF 
every other day. Bovine retinal pigment epithelial cells 
(RPE) were cultured in DMEM-F12 medium supple- 
mented with antibiotics and 10% foetal calf serum and 
kept in a 5% CO, incubator as described [18]. VAS/VEGF 
was purified from the conditioned medium of AtT20 as 
described [4]. Recombinant bFGF was provided by Dr J. 
Abraham (Scios Nova) and EGF was from Gibco. 
VAS/VEGF and bFGF were iodinated following the chlo- 
ramine T procedure [19]. Almitrine bismesylate (bis-(al- 
lylamine)-2,4 ((bis(fluoro-4 phenyl)methyl))-4 piperazinyl- 
l)-6 triazine-1,3,5 bismesylate) was obtained by chemical 
synthesis. Stock solutions. (50 mg/ml) were freshly dis- 
solved in ethanol, filtered through a 0.22 pm filter before 
use. 
2.2. Binding assays 
Subconfluent cells were washed twice with binding 
buffer (DMEM medium containing 20 mM Hepes and 1 
mg/ml gelatin) adjusted to pH 7.4 and then incubated with 
2 ng/ml of iodinated bFGF or VAS/VEGF respectively 
in a final volume of 0.25 ml as already described [19,20]. 
Non-specific binding was determined in the presence of an 
excess - 500 ng - of purified growth factor. After 3 h the 
cells were washed 3 times with cold binding buffer, once 
with 2 M NaCl in the same buffer for 2 min [21] and then 
lysed with 0.5 ml of 0.2 Ml NaOH and counted in a gamma 
counter. 
2.3. Mitogenic assays 
In the time course experiments the cells were seeded in 
DMEM containing 5% calf serum at 5,000 cells per 12-well 
cluster plates. The cell monolayers were rinsed several 
times on day 2 and almitrine was added or not. The 
medium was changed am day 4 and the cells were 
trypsinized and counted in a ZM coulter counter every 
other day. In the dose-response experiments the cells 
seeded in 2% calf serum (5,000 cells per 12-well cluster 
plates) received or not 2 ng/ml of bFGF or VAS/VEGF 
every other day and were counted on day 4. 
In parallel experiments confluent VSM were transferred 
for 24 h in serum-free DMEM. 10 ng/ml of EGF or 2 
ng/ml of bFGF were aldded to triplicate wells in the 
presence of various dilutions of almitrine. After 20 h, 1 
&i of [3H]thymidine (4.5 Ci/mmol) was added for 4 
more hours. The cells were then rinsed 3 times with 
phosphate buffer saline, 2 times with cold 10% trichloro- 
acetic acid, one more time with water. The cells were 
lysed with 0.5 ml 0.2 M NaOH and the radioactivity 
counted in a scintillation counter. 
2.4. Migration assays 
Confluent cells cultured in 12-well cluster plates were 
growth-arrested by serum starvation for 24 h. Monolayers 
were then scraped with a micropipette tip, extensively 
washed and various dilutions of the modulators were inoc- 
ulated in 1 ml of serum-free DMEM to triplicate wells. 24 
h later the cells were washed and stained with May- 
Grunwald-Giemsa [22]. The surfaces occupied by the cells 
which had migrated during this time interval were mea- 
sured in 4 different fields per well with an image analyzer 
(Biocom). 
3. Results 
Almitrine exerted a dose-dependent competition against 
iodinated bFGF binding to FBAE cells. The IC 50 value 
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Fig. 1. Inhibition of ‘ZSI-labelled bFGF and VAS/VEGF binding to 
FBAE cells by almitrine. Subconfluent FBAE cells were incubated with 2 
ng/ml of iodinated bFGF (A) or VAS/VEGF (B) and increasing concen- 
trations of almitrine (solid square) or the corresponding unlabelled growth 
factor (open square). After 2 h the cells were processed as indicated in the 
text. 
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Fig. 2. Interaction of almitrine with 1Z51-labelled bFGF and VAS/VEGF 
binding to low and high affinity sites on FBAE cells. FBAE cells were 
incubated with 2 ng/ml of labeled bFGF (A) or VAS/VEGF (B) and 
100 Kg/ml almitrine. After 2 h the cells were extracted for 2 min with 
(+) or without (-1 2 M NaCl prior NaOH cell lysis. 
corresponded to 40 pg/ml (Fig. 1A). In parallel experi- 
ments almitrine also competed with iodinated VAS/VEGF 
cell binding (Fig. 1B) with a similar efficacy (IC50 = 40 
pg/ml). Almitrine prevented the binding of bFGF to 
NaCl-sensitive as well as to NaCl-resistant binding sites 
(Fig. 2), whereas NaCl did not remove any iodinated 
VAS/VEGF. 
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Fig. 3. Inhibition by almitrine of the FBAE proliferation induced by 
serum, VAS/VEGF and bFGF. FBAE cells were inoculated with various 
doses of almitrine in presence of 2% calf serum (open square) or 2 ng/ml 
of VAS/VEGF (diamond) or bFGF.(solid square). Cells were trypsinized 
and counted on day 4. Data are presented as the mean of 3 determinations 
with a standard deviation of less of 10%. The experiment was repeated 
four times with similar results. 
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Fig. 4. Effects of almitrine on EGF and bFGF stimulated VSM prolifera- 
tion. Confluent VSM were growth arrested for 24 h in serum free DMEM 
and duplicate wells were incubated in the absence (open square) or the 
presence of 10 ng/ml EGF (diamond) or 2 ng/ml bFGF (closed square) 
with the indicated concentrations of almitrine. 20 h later the cells were 
labeled with 1 &i of [3H]thymidine for 4 h and processed as indicated 
in the text. The experiment was repeated three times with similar results. 
FBAE cells seeded at low density proliferated actively 
when exposed to DMEM supplemented with 2% calf 
serum (3 times the cell number seeded after 4 days). As 
shown in Fig. 3, the addition of almitrine inhibited the cell 
proliferation induced by serum by only 30% at a concen- 
tration of 100 pg/ml, whereas the effects of bFGF or 
VAS/VEGF could be totally abolished by almitrine. The 
inhibition was a function of the dose (IC50 of 35 and 20 
pg/ml respectively). 
Thymidine incorporation in VSM treated with almitrine 
alone was slightly increased (up to 30%) ruling out a 
mechanism of inhibition involving cytopathic effects (Fig. 
4). Almitrine did not modify DNA synthesis reinitiation 
upon EGF addition, whereas bFGF mitogenic activity was 
totally abolished by almitrine (IC 50 = 30 pg/ml). 
However, FBAE proliferation in the presence of 5% 
calf serum was reduced by almitrine and this effect was 
reversed by its removal. When the cells were exposed to 
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Fig. 5. Reversibility of the inhibition of FBAE proliferation by almitrine. 
FBAE cells were inoculated without (solid square) or with 100 pg/ml of 
almitrine for the first 2 days period (diamond) or for 8 days (open 
square). The medium was changed on day 4. Cells were trypsinized and 
counted every other day. Data are presented as the mean of 3 determina- 
tions with a standard deviation of less of 10%. The experiment was 
repeated two times with similar results. 
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Fig. 6. Inhibition of FBAE mi,gration by almitrine. Confluent growth 
arrested FBAE cell monolayers wcrc scraped with a micropipette tip and 
almitrine was added in the absence (open square) or presence of 10 
ng/ml of VAS/VEGF (solid square) or bFGF (diamond). After 24 h the 
cells were counted as indicated in the text. Data are presented as the mean 
of 3 determinations with a standard deviation of less of 10%. The 
experiment was repeated 3 times with similar results. 
almitrine for 2 days and then extensively washed, the 
proliferation was reinitiated and the slope of the curve of 
proliferation as a function of time was parallel to that 
obtained in untreated cultures (Fig. 5). 
Cells exposed to DMEM alone migrated weakly and 
cell migration was not significantly affected by almitrine 
addition. As shown in Fig. 6, when optimal concentrations 
of chemoattractants were added, the number of migrating 
cells was strongly inhibited as a function of the dose of 
almitrine (IC.50 of 12 and 5 pg/ml respectively). 
Almitrine inhibited bF(GF binding to BBC, VSM and 
RPE cells (Table 1) and tihat of VAS/VEGF to BBC and 
RPE. Similar concentratisons of almitrine also inhibited 
their proliferation. However, the IC50 corresponding to 
VAS/VEGF was constantly 2-3 times lower than that 
obtained for bFGF. 
4. Discussion 
In this report we show that almitrine reduces the biolog- 
ical activities exerted by serum and basic growth factors in 
vitro. 
Table 1 
Inhibition by almitrine of bFGF and VAS/VEGF binding and prolifera- 
tion on various normal cells. Cells were seeded and processed as de- 
scribed in the legends of Figs. 1 and 3 for binding and proliferation 
assays, respectively. IC50 values of almitrine, expressed in pg/ml, are 
the means of 3 determinations with a standard deviation of less than 10%. 
n.d.: not determined since VSM do not bind VAS/VEGF 
Binding Proliferation 
- 
bFGF VAS/VlEGf bFGF VAS/VEGF 
FBAE 40 4.0 
VSM 100 n.d. 
BBC 45 45 
RPE 80 65 
35 20 
125 n.d. 
35 15 
50 35 
Almitrine reduced their binding to vascular endothelial 
cells. Several mechanisms of interference may reduce the 
binding of basic growth factors to their cellular receptors. 
bFGF for instance must bind to low affinity receptors 
represented by proteoheparansulfates [23] to bind to its 
high affinity receptors. One simple mean of distinguishing 
between these interactions consists of eluting the iodinated 
bFGF bound by high salt concentrations [21]. Almitrine 
inhibits the binding of bFGF to low affinity and in a minor 
extent to high affinity receptors. In contrast, despite its 
high p1 and its affinity for proteoheparansulfates, iodinated 
mammalian VAS/VEGF is not removed by high salt 
washing. This confirms our previous results using adrenal 
cortex capillary derived endothelial cells as target cells 
[19]. VAS/VEGF 165 synthesized by insect cells infected 
by a recombinant baculovirus is however removed by 
NaCl, probably through different interactions of proteohep- 
aransulfates and sugar moieties (Favard et al., in prepara- 
tion). Almitrine is a positively charged molecule (pKa of 
3.8 and 5.6), thus its competition with basic growth factors 
might, at least partly, account for electrostatic interactions 
with heparin or high affinity receptors rather than with the 
growth factors themselves. 
The physiological role of these ligand-receptor interac- 
tions was studied on growth factor-mediated cell prolifera- 
tion and migration. In order to confirm that the electro- 
static interactions induced these inhibitions, almitrine was 
also added to the negatively charged growth factor EGF. 
No inhibition of cell proliferation was observed. In con- 
trast when basic growth factors were added to the cultures, 
both cellular functions were inhibited by almitrine. How- 
ever, the concentrations providing half the maximal inhibi- 
tion of migration were 5-fold lower than those required for 
a similar effect on cell proliferation. Although FBAE 
might express several genes coding for VAS/VEGF or 
bFGF receptors, it is not known whether or not these 
different receptors are redundant for the 2 biological ef- 
fects. The observed variation in IC50 might therefore 
reflect different K, for several receptors which might 
transduce different biological actions. Alternatively, in ad- 
dition to its interactions with cell surface receptors, 
almitrine could interfere with various enzymatic pathways 
important for cell proliferation or migration. These interac- 
tions might be exerted with lower doses than those re- 
quired to prevent the binding of growth factors to their cell 
surface receptors. However, almitrine effects cannot be 
contributed by toxicity since the cells retained a weak 
ability to grow in its presence and also could proliferate 
actively after its removal. Almitrine inhibition of bFGF 
and VAS/VEGF functions was not restricted to large 
vessels derived endothelial cells. Other endothelial cells 
derived from brain capillaries as well as smooth muscle or 
retinal pigment epithelial cells were also affected by 
almitrine in a similar fashion. 
The mechanism of action of almitrine seems different 
from suramin, a negatively charged molecule which in- 
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hibits the binding of bFGF [13], VAS/VEGF [19], EGF 
[24] and transforming growth factor /? [25] to their recep- 
tors. Suramin is thought to act through several pathways 
such as direct binding to growth factors and inhibition of 
protein kinase C, phosphatidylinositol kinase, diacyl- 
glycerol kinase [26,27] or topoisomerase II [28]. It inhibits 
endothelial cell proliferation and migration at doses 6-10 
times higher than that required for inhibition by almitrine 
[29]. In contrast to almitrine, the IC50 for proliferation or 
migration corresponds to 5 times the IC50 for bFGF 
cellular binding. 
Almitrine has long been used in association (DUXIL* > 
with another basic molecule, the raubasine, to reduce the 
damages caused by hypoxia to neural tissues [30]. How- 
ever, raubasine does not affect the binding, the prolifera- 
tion or the migration of cells stimulated by basic growth 
factors (not shown). Recent reports have shown that 
VAS/VEGF expression is enhanced by hypoxia [31,32] 
and therefore might lead to angiogenesis. It is therefore 
tempting to speculate that almitrine might act by counter- 
acting the effects of VAS/VEGF overexpression observed 
in hypoxia-driven angiogenesis such as diabetic retinopa- 
thy or tumor progression. 
Further studies conducted in vivo should provide infor- 
mation on the actual role of almitrine in counteracting 
overexpression of bFGF and VAS/VEGF. 
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